Medizinische Universität Innsbruck, Innsbruck, Austria.
Radiother Oncol. 2010 Sep;96(3):280-7. doi: 10.1016/j.radonc.2010.07.022. Epub 2010 Aug 17.
During the last decade several different PET radiopharmaceuticals entered into the clinic and positron emission tomography (PET) became an important tool for staging of cancer patients and assessing response to therapy. Meanwhile FDG-PET has also found application in radiation treatment planning. Potential radiopharmaceuticals for radiation treatment planning may also include tracers allowing monitoring of proliferation, amino acid metabolism, hypoxia, lipid metabolism and receptor expression. Here the syntheses of a selection of clinically tested promising tracers are summarized and the different molecular mechanisms for accumulation are discussed which may help to choose the appropriate tracer for planning radiation treatment strategies.
在过去的十年中，有几种不同的 PET 放射性药物进入临床，正电子发射断层扫描（PET）成为癌症患者分期和评估治疗反应的重要工具。同时，FDG-PET 也已应用于放射治疗计划。用于放射治疗计划的潜在放射性药物也可能包括允许监测增殖、氨基酸代谢、缺氧、脂肪代谢和受体表达的示踪剂。在这里，总结了一些经过临床测试的有前途的示踪剂的合成，并讨论了不同的积累分子机制，这可能有助于为放射治疗策略的规划选择合适的示踪剂。
